Javascript must be enabled to continue!
Data from Missense Mutant p53 Transactivates Wnt/β-Catenin Signaling in Neighboring p53-Destabilized Cells through the COX-2/PGE2 Pathway
View through CrossRef
<div>Abstract<p>Missense-type p53 mutations have shown to acquire novel oncogenic roles through a gain-of-function mechanism. However, there is intratumor heterogeneity in stabilization of mutant p53 protein, and it has not been well understood about the interaction between p53-stabilized and -destabilized cells in the same tumors. We established mouse intestinal tumor–derived organoids carrying <i>Apc</i><sup>Δ716</sup>, <i>Kras</i><sup>G12D</sup>, and <i>Tgfbr2</i><sup>−/−</sup> mutations with <i>Trp53</i><sup>R270H</sup> or <i>Trp53</i><sup>Null</sup> mutation (AKTP<sup>R270H</sup> and AKTP<sup>Null</sup>, respectively). Using these organoids, we found that the activation level of Wnt/β-catenin signaling is significantly higher in AKTP<sup>R270H</sup> cells compared with AKTP<sup>Null</sup> cells. Notably, Wnt activation in the AKTP<sup>Null</sup> cells was significantly increased when co-cultured with AKTP<sup>R270H</sup> cells. Expression analysis revealed that COX-2 is significantly upregulated in AKTP<sup>R270H</sup> but not in AKTP<sup>Null</sup> cells, suggesting that mutant p53 induces the COX-2/prostaglandin E2 (PGE2) pathway. Importantly, Wnt activation in co-cultured AKTP<sup>Null</sup> cells with AKTP<sup>R270H</sup> was significantly suppressed when treated with the inhibitor of COX-2 or PGE2 receptors EP2/EP4. Furthermore, stimulation with PGE2 increased Wnt signaling activity in AKTP<sup>Null</sup> cells. These results indicate that the COX-2/PGE2 pathway is activated in the p53-stabilized cells in the missense-type p53-mutant cancer, and secreted PGE2 may transactivate Wnt/β-catenin signaling in neighboring p53-destabilized tumor cells in the intratumor microenvironment. Therefore, targeting stabilized mutant p53 or the COX-2/PGE2 pathway may suppress Wnt/β-catenin signaling of both mutant p53–stabilized and –destabilized cells; thus, this can be a possible preventive or therapeutic strategy.</p>Significance:<p>There is intratumor heterogeneity in the stabilization of missense mutant p53, and it has been thought that only cells with nuclear accumulation of mutant p53 have oncogenic function. However, using mouse intestinal tumor–derived organoids, we show that mutant p53–stabilized cells transactivate Wnt/β-catenin signaling in neighboring p53-destabilized cells through activating the COX-2/PGE2 pathway. These results suggest that both p53-stabilized cells and p53-destabilized cells contribute to malignant progression through interaction within the intratumor microenvironment.</p></div>
American Association for Cancer Research (AACR)
Title: Data from Missense Mutant p53 Transactivates Wnt/β-Catenin Signaling in Neighboring p53-Destabilized Cells through the COX-2/PGE2 Pathway
Description:
<div>Abstract<p>Missense-type p53 mutations have shown to acquire novel oncogenic roles through a gain-of-function mechanism.
However, there is intratumor heterogeneity in stabilization of mutant p53 protein, and it has not been well understood about the interaction between p53-stabilized and -destabilized cells in the same tumors.
We established mouse intestinal tumor–derived organoids carrying <i>Apc</i><sup>Δ716</sup>, <i>Kras</i><sup>G12D</sup>, and <i>Tgfbr2</i><sup>−/−</sup> mutations with <i>Trp53</i><sup>R270H</sup> or <i>Trp53</i><sup>Null</sup> mutation (AKTP<sup>R270H</sup> and AKTP<sup>Null</sup>, respectively).
Using these organoids, we found that the activation level of Wnt/β-catenin signaling is significantly higher in AKTP<sup>R270H</sup> cells compared with AKTP<sup>Null</sup> cells.
Notably, Wnt activation in the AKTP<sup>Null</sup> cells was significantly increased when co-cultured with AKTP<sup>R270H</sup> cells.
Expression analysis revealed that COX-2 is significantly upregulated in AKTP<sup>R270H</sup> but not in AKTP<sup>Null</sup> cells, suggesting that mutant p53 induces the COX-2/prostaglandin E2 (PGE2) pathway.
Importantly, Wnt activation in co-cultured AKTP<sup>Null</sup> cells with AKTP<sup>R270H</sup> was significantly suppressed when treated with the inhibitor of COX-2 or PGE2 receptors EP2/EP4.
Furthermore, stimulation with PGE2 increased Wnt signaling activity in AKTP<sup>Null</sup> cells.
These results indicate that the COX-2/PGE2 pathway is activated in the p53-stabilized cells in the missense-type p53-mutant cancer, and secreted PGE2 may transactivate Wnt/β-catenin signaling in neighboring p53-destabilized tumor cells in the intratumor microenvironment.
Therefore, targeting stabilized mutant p53 or the COX-2/PGE2 pathway may suppress Wnt/β-catenin signaling of both mutant p53–stabilized and –destabilized cells; thus, this can be a possible preventive or therapeutic strategy.
</p>Significance:<p>There is intratumor heterogeneity in the stabilization of missense mutant p53, and it has been thought that only cells with nuclear accumulation of mutant p53 have oncogenic function.
However, using mouse intestinal tumor–derived organoids, we show that mutant p53–stabilized cells transactivate Wnt/β-catenin signaling in neighboring p53-destabilized cells through activating the COX-2/PGE2 pathway.
These results suggest that both p53-stabilized cells and p53-destabilized cells contribute to malignant progression through interaction within the intratumor microenvironment.
</p></div>.
Related Results
Bortezomib Induces Activation of b-Catenin/TCF Signaling Pathway in Multiple Myeloma
Bortezomib Induces Activation of b-Catenin/TCF Signaling Pathway in Multiple Myeloma
Abstract
Abstract 1851
Background:
The proteasome inhibitor Bortezomib (Bz) shows significant activity in Multipl...
Abstract 1706: Investigating the interaction between ETS family members and mutant p53
Abstract 1706: Investigating the interaction between ETS family members and mutant p53
Abstract
Cancer cases are on the rise globally requiring a deeper understanding of the disease and identification of novel therapeutic targets. Mutations in genes of...
Abstract 422: Novel approach to destabilization of oncogenic mutant p53 and therapeutic implications
Abstract 422: Novel approach to destabilization of oncogenic mutant p53 and therapeutic implications
Abstract
Introduction: Mutant p53 drives several hallmarks of cancer through a gain-of-function oncogenic program. The oncogenicity of mutant p53 includes sustained ...
Abstract 1584: Wnt/beta-catenin and Foxa2 axis activates AR signaling in castration resistant prostate cancer
Abstract 1584: Wnt/beta-catenin and Foxa2 axis activates AR signaling in castration resistant prostate cancer
Abstract
Background: Prostate cancer (PCa) is the leading cancer among men in the world. Androgen deprivation therapy is a common treatment to cease prostate growth....
Liposome Loaded Prostaglandin E2 (PGE2) for Muscle Regeneration
Liposome Loaded Prostaglandin E2 (PGE2) for Muscle Regeneration
Prostaglandin E2 (PGE2) is an FDA approved lipid signaling molecule for range of disorders. Also, it has a significant therapeutic potential for tissue repair and regeneration. How...
Abstract 5177: E7386 : First-in-class orally active CBP/beta-catenin modulator as an anticancer agent
Abstract 5177: E7386 : First-in-class orally active CBP/beta-catenin modulator as an anticancer agent
Abstract
Carcinogenesis is often accelerated by the aberrant activation of components molecules of Wnt signaling pathway, especially, APC and beta-catenin are freque...
Ethacrynic Acid Can Inhibit Wnt/β-Catenin Signaling and Induce Apoptosis in Chronic Lymphocytic Leukemia Cells.
Ethacrynic Acid Can Inhibit Wnt/β-Catenin Signaling and Induce Apoptosis in Chronic Lymphocytic Leukemia Cells.
Abstract
Chronic lymphocytic leukemia (CLL) is caused by an abnormal balance in signals for survival and cell death. Recently, CLL cells are shown to have an activat...
Data from Constitutive Activation of DNA Damage Checkpoint Signaling Contributes to Mutant p53 Accumulation via Modulation of p53 Ubiquitination
Data from Constitutive Activation of DNA Damage Checkpoint Signaling Contributes to Mutant p53 Accumulation via Modulation of p53 Ubiquitination
<div>Abstract<p>Many mutant p53 proteins exhibit an abnormally long half-life and overall increased abundance compared with wild-type p53 in tumors, contributing to mut...

